Drug Trial Radar · NCT07173855
Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,853
Planned (sponsor's estimate)
Start
Nov 25, 2025
Primary completion
Mar 1, 2027
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- Scarborough General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Scarborough Health Network; Lakeridge Health Corporation
- First posted
- Sep 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium when levels are below certain targets. However, the best targets are unknown. The goal of this clinical trial is to study protocols for magnesium supplementation in people with critical illness, comparing a protocol with higher target level to a protocol with a lower target level. The main question this study aims to answer is whether magnesium supplementation protocols targeting a higher or lower level lead to better 30-day survival and less atrial fibrillation. Participants will not have to do any specific tasks, undergo any additional tests, or complete any surveys.
Conditions
- Critical Illness
Interventions
Magnesium sulfate administrationDrug
Magnesium sulfate is used in both arms for magnesium replacement.
Magnesium oxideDrug
In the higher-target arm, magnesium oxide 420mg po q12h x 2 is one of the options available for magnesium replacement when magnesium levels lie between 0.75 and 0.95mmol/L.
Magnesium glucoheptonateDrug
Magnesium glucoheptonate 30mL po q12h x 2 is an oral option for magnesium replacement in the higher-target arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 30-day ordinal composite of hospital mortality and days free of atrial fibrillation in ICUTime frame: 30 days after enrollment.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Lakeridge Health Ajax-Pickering
Ajax, Ontario, Canada · Recruiting
Lakeridge Health Bowmanville
Bowmanville, Ontario, Canada · Recruiting
Lakeridge Health Oshawa
Oshawa, Ontario, Canada · Recruiting
Scarborough Centenary Hospital
Toronto, Ontario, Canada · Recruiting
Scarborough General Hospital
Toronto, Ontario, Canada · Recruiting
Scarborough Birchmount Hospital
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.